US2008009536A1PendingUtilityA1

Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure

61
Individually held — no corporate assignee on recordPriority: Aug 10, 2002Filed: Aug 7, 2007Published: Jan 10, 2008
Est. expiryAug 10, 2022(expired)· nominal 20-yr term from priority
Inventors:Harrihar A. Pershadsingh
A61P 5/48A61P 3/06A61P 9/00A61P 9/04A61P 43/00A61P 3/10A61P 7/02A61P 9/10A61P 9/12A61P 3/04A61P 29/00A61P 3/00A61P 13/12A61K 31/41A61K 31/4184A61P 1/16A61K 31/415
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes. Compounds are provided that antagonize or block the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs), can be used to treat or prevent diseases known to be treatable or preventable by PPAR activators and were not previously recognized to be therapeutic targets for angiotensin II receptor antagonists.

Claims

exact text as granted — not AI-modified
1 . A method for treating or limiting the rate of progression of polycystic kidney disease, comprising orally administering to a mammal in need thereof a therapeutically effective amount of a compound sufficient to (a) at least partially activate peroxisome proliferator activated receptor-gamma (PPAR-gamma) and (b) at least partially inhibit, antagonize or block an activity of angiotensin II type 1 receptors, wherein the therapeutically effective amount is about 20 mg to about 1000 mg.  
     
     
         2 . The method of  claim 1  wherein the compound is administered in a pharmaceutically acceptable form.  
     
     
         3 . The method of  claim 1  wherein the compound is telmisartan or an analog thereof.  
     
     
         4 . The method of  claim 1  wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease and the compound is telmisartan.  
     
     
         5 . The method of  claim 1  wherein the compound is telmisartan and the effective daily orally administered dose of telmisartan is about 80 mg.  
     
     
         6 . The method of  claim 1  wherein the compound is telmisartan and the effective daily orally administered dose of telmisartan is about 160 mg.  
     
     
         7 . The method of  claim 1  wherein the compound is telmisartan and the telmisartan is administered in combination with ramipril.  
     
     
         8 . The method of  claim 1  wherein the compound is telmisartan and the telmisartan is administered in combination with lisinopril.  
     
     
         9 . The method of  claim 7  wherein 1 part by weight of telmisartan is administered in combination with 0.01 to 100 parts by weight of ramipril.  
     
     
         10 . The method of  claim 8  wherein 1 part by weight of telmisartan is administered in combination with 0.01 to 100 parts by weight of lisinopril.  
     
     
         11 . The method of  claim 9  wherein the telmisartan and the ramipril are administered as separate compositions.  
     
     
         12 . The method of  claim 9  wherein the telmisartan and the ramipril are administered as a single composition.  
     
     
         13 . The method of  claim 10  wherein the telmisartan and the lisinopril are administered as separate compositions.  
     
     
         14 . The method of  claim 10  wherein the telmisartan and the lisinopril are administered as a single composition.  
     
     
         15 . The method of  claim 1  wherein the mammal is a human child, adolescent or adult.  
     
     
         16 . A composition comprising 1 part by weight of telmisartan and 0.01 to 100 parts by weight of ramipril.  
     
     
         17 . A composition comprising 1 part by weight of telmisartan and 0.01 to 100 parts by weight of lisinopril.  
     
     
         18 . An article of manufacture comprising a composition comprising 1 part by weight of telmisartan and a composition comprising 0.01 to 100 parts by weight of ramipril.  
     
     
         19 . The article of manufacture of  claim 18  wherein the telmisartan and the ramipril are in separate compositions.  
     
     
         20 . The article of manufacture of  claim 18  wherein the telmisartan and the ramipril are in a single composition.  
     
     
         21 . An article of manufacture comprising a composition comprising 1 part by weight of telmisartan and a composition comprising 0.01 to 100 parts by weight of lisinopril.  
     
     
         22 . The article of manufacture of  claim 21  wherein the telmisartan and the lisinopril are in separate compositions.  
     
     
         23 . The article of manufacture of  claim 21  wherein the telmisartan and the lisinopril are in a single composition.

Join the waitlist — get patent alerts

Track US2008009536A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.